Last updated: September 1, 2026
Elagolix-based products occupy a specialized women’s-health market led by AbbVie. The portfolio consists primarily of Orilissa, an elagolix sodium product for endometriosis-associated pain, and Oriahnn, a fixed-dose regimen containing elagolix sodium, estradiol, and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids. Both products face a constrained commercial opportunity because of treatment-duration limits, safety monitoring, competing hormonal therapies, and the absence of a large long-term maintenance population.
Public filings do not separately disclose revenue for Orilissa and Oriahnn. AbbVie reports these products within broader product categories, limiting precise product-level valuation. The financial trajectory is therefore best assessed through prescription demand, indication expansion, market access, patent timing, and the rate at which newer oral and long-acting therapies compete for the same patients.
What are elagolix sodium, Orilissa, and Oriahnn?
Elagolix is an oral, nonpeptide gonadotropin-releasing hormone antagonist. It suppresses luteinizing hormone and follicle-stimulating hormone, reducing ovarian estrogen production.
| Product |
Active ingredients |
FDA indication |
Initial U.S. approval |
Sponsor |
| Orilissa |
Elagolix sodium |
Moderate-to-severe pain associated with endometriosis |
2018 |
AbbVie |
| Oriahnn |
Elagolix sodium, estradiol, norethindrone acetate |
Heavy menstrual bleeding associated with uterine fibroids in premenopausal women |
2020 |
AbbVie |
Orilissa is available as 150 mg once daily and 200 mg twice daily. The 200 mg twice-daily dose is generally used for patients with dyspareunia or more severe symptoms but has a shorter approved treatment duration.
Oriahnn uses a two-capsule daily regimen. The morning capsule contains elagolix 300 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg. The evening capsule contains elagolix 300 mg. The estradiol and norethindrone acetate components provide add-back therapy intended to reduce hypoestrogenic effects and protect the endometrium.
How large is the elagolix market?
The addressable market is substantial in epidemiological terms but narrower commercially because diagnosis rates, treatment persistence, reimbursement, and duration limits reduce the treated population.
Endometriosis affects approximately 10% of reproductive-age women globally, according to the World Health Organization. Uterine fibroids are also common, with prevalence estimates varying by age, race, imaging method, and study design [1,2].
The commercial market is divided among:
- Combined oral contraceptives and progestins
- Levonorgestrel-releasing intrauterine systems
- GnRH agonists
- GnRH antagonists
- Tranexamic acid and nonsteroidal anti-inflammatory drugs
- Surgery, including hysterectomy and myomectomy
- Newer oral combination products
Elagolix competes on oral administration, rapid reversibility, and dose-dependent ovarian suppression. Its principal weakness is the limited duration of use caused by bone mineral density loss and other hypoestrogenic effects.
What drives demand for Orilissa and Oriahnn?
Endometriosis demand
Orilissa targets patients whose symptoms are inadequately controlled by contraceptives, progestins, or analgesics. The product can delay or avoid surgery for some patients, but treatment is usually managed as a limited-duration intervention rather than lifelong maintenance.
The endometriosis opportunity benefits from:
- Greater disease awareness
- Long diagnostic delays
- Increased use of specialist care
- Demand for non-surgical treatments
- Limited efficacy of existing analgesic-only regimens
The market remains difficult because endometriosis is heterogeneous. Pain severity, lesion location, infertility concerns, and prior surgery affect treatment selection. Many patients cycle through several therapies, producing prescription opportunity but also high discontinuation rates.
Uterine fibroid demand
Oriahnn treats heavy menstrual bleeding rather than the full structural disease burden of uterine fibroids. The product is most commercially relevant for patients seeking to avoid or delay surgery, particularly before menopause.
The U.S. label limits use to 24 months because of bone loss concerns. That restriction reduces lifetime revenue per patient and creates recurring dependence on new patient starts. A patient who responds well cannot remain on therapy indefinitely under the approved labeling.
How do Orilissa and Oriahnn compare with competing drugs?
| Therapy |
Main use |
Commercial advantage |
Principal limitation |
| Orilissa |
Endometriosis pain |
Oral, rapid suppression, dose flexibility |
Treatment-duration limits and hypoestrogenic effects |
| Oriahnn |
Fibroid-related heavy bleeding |
Direct symptom control with add-back therapy |
24-month limit, complex dosing, thromboembolic warnings |
| Relugolix combination products |
Fibroids and endometriosis |
Once-daily combination therapy, broader positioning in some markets |
Similar safety, cost, and duration considerations |
| Leuprolide |
Fibroids and other hormone-sensitive conditions |
Established clinical history |
Injection, flare effect, hypoestrogenic adverse effects |
| LNG-IUD |
Heavy menstrual bleeding |
Long duration and local delivery |
Placement barriers and variable suitability |
| Progestins and oral contraceptives |
Endometriosis and bleeding |
Low cost and broad familiarity |
Variable efficacy and tolerability |
| Surgery |
Fibroids and endometriosis |
Definitive or durable intervention in selected cases |
Invasiveness, fertility impact, recovery |
The closest branded threat is the oral GnRH antagonist class. Myovant Sciences and Pfizer commercialized Myfembree, containing relugolix, estradiol, and norethindrone acetate. Myfembree received U.S. approvals for fibroid-related heavy menstrual bleeding and endometriosis-associated pain. The product has a once-daily regimen and a single-tablet format, which can be commercially attractive relative to Oriahnn’s morning-and-evening capsule schedule [3].
The competitive difference is not limited to pharmacology. Payer coverage, prior authorization, copay support, gynecologist familiarity, and manufacturer contracting can determine market share.
What is the financial trajectory for elagolix products?
AbbVie does not report standalone net sales for Orilissa or Oriahnn in its annual filings. The products are included in broader reporting categories, and publicly available company disclosures do not provide a clean product-level revenue series for the elagolix franchise [4].
The financial trajectory can be characterized in four stages:
2018 to 2019: launch and early adoption
Orilissa entered the market as the first oral GnRH antagonist specifically approved in the United States for endometriosis pain. Initial adoption depended on specialist prescribing and payer access. Early commercial growth was supported by the unmet need for non-surgical pain treatment.
2020 to 2021: indication expansion and pandemic disruption
Oriahnn expanded the franchise into uterine fibroids in 2020. The launch occurred during the COVID-19 period, which disrupted physician visits, elective procedures, diagnosis, and new prescription initiation. Fibroid patients who might otherwise have received surgery or preoperative medical therapy experienced changes in care pathways.
2022 to 2024: class competition and maturity
The franchise entered a more competitive phase as relugolix combination products gained access to the same gynecologic prescriber base. Orilissa’s revenue potential became increasingly dependent on new patient starts, persistence through treatment cycles, and reimbursement rather than broad population expansion.
Medium term: replacement and lifecycle management
The mature commercial question is whether AbbVie can retain prescribers and patients as oral GnRH antagonists become more interchangeable. Product differentiation depends on indication-specific efficacy, dosing, add-back design, safety monitoring, and payer economics.
Because of duration restrictions, neither product has the profile of a chronic autoimmune or oncology therapy. Revenue is more likely to stabilize at a specialty level than to compound indefinitely.
When do elagolix products lose exclusivity?
U.S. exclusivity is determined by multiple patent families, regulatory exclusivity provisions, pediatric extensions, and litigation outcomes. Elagolix protection is not represented by one universal expiration date because Orilissa and Oriahnn may rely on different listed patents covering the active ingredient, formulations, methods of use, and combination regimens.
The principal legal risk categories are:
| Protection category |
Relevance |
| Elagolix compound patents |
Can delay generic elagolix products across indications |
| Salt and solid-form patents |
May protect elagolix sodium and pharmaceutical compositions |
| Dosage-form patents |
Can cover tablets, capsules, strength combinations, or release characteristics |
| Method-of-use patents |
Can cover treatment of endometriosis pain or fibroid-related bleeding |
| Combination patents |
Can protect elagolix with estradiol and norethindrone acetate |
| Regulatory exclusivity |
Provides a separate FDA-based barrier from patent rights |
FDA Orange Book entries are the controlling public source for listed patents and pediatric exclusivity. Patent expiration dates can change in practical effect through terminal disclaimers, patent-term adjustment, patent-term extension, or successful Paragraph IV litigation [5].
A generic applicant seeking approval before listed patent expiry can file an Abbreviated New Drug Application with a Paragraph IV certification. The certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. The patent holder generally has 45 days to file suit. A timely suit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court developments [6].
Are there Paragraph IV challenges to elagolix?
Paragraph IV risk is commercially material because elagolix products have finite treatment durations and high branded pricing relative to conventional hormonal therapies. A generic entrant could target the active ingredient, a specific strength, or a narrow indication.
The most relevant generic scenarios are:
- A generic elagolix product for endometriosis using Orilissa-listed patents as the reference protection.
- A generic combination product containing elagolix, estradiol, and norethindrone acetate for fibroid-related bleeding.
- A product that seeks approval for one strength or indication while avoiding other formulation or method patents.
- An at-risk launch following a favorable district court ruling or settlement.
The commercial impact of a generic challenge depends on whether the entrant substitutes for Orilissa, Oriahnn, or both. A generic single-agent product would not necessarily replicate the clinical and regulatory profile of the fixed-dose Oriahnn regimen.
Current litigation and Orange Book status require live review of FDA and court dockets. Static patent summaries can become outdated after settlements, dismissals, amended listings, or appellate decisions.
What is the FDA regulatory status of Orilissa and Oriahnn?
Both products are FDA-approved prescription drugs, not biologics. Biosimilar risk is therefore not applicable. The relevant follow-on pathway is the ANDA pathway for generics, or potentially a 505(b)(2) application for a product that relies partly on existing evidence but differs in formulation, combination, or labeling.
FDA-approved limitations materially affect commercial value:
- Orilissa has dose- and duration-specific restrictions.
- Oriahnn is limited to a maximum of 24 months.
- Both products carry warnings related to bone mineral density loss.
- Oriahnn contains estrogen and progestin, creating additional thromboembolic and cardiovascular considerations.
- Patient selection and contraindication screening affect prescribing.
These restrictions reduce the probability that either product becomes a broad first-line therapy.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than extreme. Elagolix is a small molecule, so it does not have the manufacturing complexity associated with monoclonal antibodies, cell therapies, or complex peptides.
The main barriers include:
- Controlled synthesis and impurity management for elagolix
- Reproducible production of elagolix sodium
- Bioequivalence across multiple strengths
- Combination-product manufacturing for Oriahnn
- Stability of estradiol and norethindrone acetate
- Packaging and labeling for the two-dose regimen
- Clinical bridging for alternative formulations
- Patent claim separation across single-agent and combination products
A generic manufacturer may face greater development complexity with Oriahnn than with a conventional single-ingredient tablet. The need to demonstrate bioequivalence for multiple active ingredients can increase development and regulatory cost.
Which companies are challenging the elagolix franchise?
The principal commercial challengers are manufacturers of alternative hormonal therapies and oral GnRH antagonists.
Relugolix competitors
Myfembree is the closest branded comparator because it combines a GnRH antagonist with estradiol and norethindrone acetate. Its once-daily administration creates a direct convenience comparison with Oriahnn.
Generic manufacturers
Potential generic competition can come from large ANDA developers with experience in hormonal products, women’s health, and complex oral combinations. The practical threat depends on patent certifications, litigation outcomes, manufacturing readiness, and FDA approval timing.
Low-cost alternatives
Progestins, combined oral contraceptives, tranexamic acid, NSAIDs, and intrauterine systems exert price pressure even without directly substituting for elagolix. These therapies can prevent physicians from moving patients to a high-cost GnRH antagonist.
How strong is the elagolix patent estate?
The estate is strategically stronger when viewed as a layered portfolio rather than as a single active-ingredient patent. The principal strengths are the clinical differentiation of approved indications, combination-product claims, and multiple dosing configurations.
Its weaknesses are equally clear:
- Small-molecule products are generally vulnerable to ANDA competition.
- Treatment-duration limits restrict lifetime value.
- Alternative GnRH antagonists reduce switching costs for prescribers.
- Some patients can use low-cost therapies or surgery.
- A generic single-agent product could weaken price expectations even if the full Oriahnn regimen remains protected.
Overall, the estate should be viewed as commercially meaningful but not structurally comparable to a high-barrier biologic or a drug with a large chronic-use population.
What generic launch scenarios exist?
Early launch after settlement
A settlement could allow a generic launch before the latest listed patent expiration. The launch might be licensed, volume-limited, or restricted to one dosage strength.
First-filer exclusivity
If an ANDA applicant qualifies as a first Paragraph IV filer, it may receive 180 days of generic exclusivity, subject to forfeiture rules and other statutory conditions. This can delay additional generic competition while accelerating erosion of branded sales [6].
At-risk launch
A manufacturer could launch before final resolution of patent litigation. This creates potential damages exposure if the patents are later upheld.
Post-expiration entry
Multiple generic manufacturers could enter after the relevant Orange Book patents expire or are invalidated. The steepest price decline would likely affect Orilissa single-agent products first, while the fixed-dose combination may have fewer immediate competitors.
What geographic markets matter?
The United States is the main commercial market for these products because AbbVie’s largest public disclosures, FDA approvals, and branded reimbursement structure are U.S.-centered.
International opportunities are more limited by:
- Different regulatory approvals
- National reimbursement controls
- Availability of surgery and low-cost hormonal therapy
- Variations in endometriosis and fibroid treatment guidelines
- Local patent rights
- Country-specific pricing and reference-pricing systems
A U.S. patent event does not automatically create generic entry in Europe, Japan, Canada, or emerging markets. Market-by-market patent and regulatory analysis is required.
Key Takeaways
- Orilissa contains elagolix sodium and treats endometriosis-associated pain.
- Oriahnn contains elagolix sodium, estradiol, and norethindrone acetate and treats heavy menstrual bleeding caused by uterine fibroids.
- AbbVie does not separately disclose revenue for the two products, preventing a reliable public product-level sales forecast.
- The franchise benefits from unmet need but is constrained by treatment-duration limits and hypoestrogenic safety risks.
- Myfembree, progestins, oral contraceptives, intrauterine systems, and surgery are major competitive alternatives.
- Generic risk centers on Orange Book patents covering elagolix, formulations, dosing regimens, combinations, and methods of use.
- Biosimilar competition is irrelevant because elagolix is a small-molecule drug.
- The likely financial profile is specialty-scale revenue with mature or declining growth as oral GnRH antagonist competition expands.
- Oriahnn may face higher generic development complexity than single-agent elagolix because it contains three active ingredients and uses a two-capsule regimen.
- Exact entry timing depends on current FDA Orange Book listings, patent litigation, Paragraph IV certifications, settlements, and any patent-term adjustments.
FAQs
Is Oriahnn the same drug as Orilissa?
No. Both contain elagolix sodium, but Orilissa is an elagolix-only product for endometriosis pain. Oriahnn combines elagolix with estradiol and norethindrone acetate for fibroid-related heavy menstrual bleeding.
Can Oriahnn be used indefinitely?
No. FDA labeling limits Oriahnn treatment to 24 months because of bone mineral density concerns.
Does a generic elagolix tablet automatically substitute for Oriahnn?
No. A single-agent elagolix product would not automatically be therapeutically or legally equivalent to the fixed-dose combination of elagolix, estradiol, and norethindrone acetate.
Is elagolix exposed to biosimilar competition?
No. Elagolix is a chemically synthesized small molecule. Follow-on competition would generally proceed through generic-drug pathways rather than biosimilar approval.
Which product has greater commercial durability, Orilissa or Oriahnn?
Orilissa has a larger disease market because endometriosis is widespread, but it faces strong competition from multiple hormonal treatments. Oriahnn has a differentiated combination regimen but a narrower indication and a 24-month treatment limit. Neither product has the durability of a broadly used chronic therapy.
References
-
World Health Organization. (2023). Endometriosis. https://www.who.int/news-room/fact-sheets/detail/endometriosis
-
American College of Obstetricians and Gynecologists. (2021). Uterine fibroids. https://www.acog.org/womens-health/faqs/uterine-fibroids
-
U.S. Food and Drug Administration. (2021). FDA approves new treatment for uterine fibroids. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uterine-fibroids
-
AbbVie Inc. (2024). 2023 annual report. https://www.abbvie.com/investor-relations/financial-reports-and-filings.html
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman letters. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters-controls-and-exclusivity-information-letters-companion-products-crls-and-grls
